All In Biotech

Drug Trial Radar · NCT07541001

PRL3-Zumab in Patients With Advanced Solid Tumors

An Open Label, Multicenter, Safety and Efficacy Phase II Study of PRL3-Zumab in Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 30, 2021

Primary completion

Jun 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Intra-IMMUSG Pte LtdIndustry
Sponsor type
Industry
Collaborators
The First Affiliated Hospital of Xiamen University; Shanghai Chest Hospital; Hubei Cancer Hospital; Henan Cancer Hospital; Beijing Friendship Hospital; Fujian Provincial Hospital; Hangzhou Cancer Hospital
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors. PRL3-zumab will be administered via intravenous (IV) infusion until discontinuation criteria are met (e.g., disease progression per RECIST v1.1/iRECIST, intolerable toxicity, or withdrawal of consent). Study Periods and Duration The study is divided into the following phases: * Screening Period: Day -21 to Day -1; all assessments must be completed prior to the first dose. * Treatment Period: One cycle is defined as 4 weeks, consisting of two infusions administered 2 weeks apart. * End-of-Treatment (EOT) Visit: To be conducted within 14 days of the last dose or treatment discontinuation. * Safety Follow-Up: A visit scheduled 30 days after the last dose. * Survival Follow-Up: Conducted every 3 months post-discontinuation via telephone or other appropriate methods until the data cutoff date. Assessments * Safety \& QoL: Safety assessments (including laboratory tests) will be performed prior to each infusion. Quality of Life (QoL) will be assessed at screening and every 8 weeks during treatment. * Tumor Imaging: Assessments will be performed at baseline and every 8 weeks following the initiation of study treatment, according to RECIST v1.1 and iRECIST. * Immunogenicity: Assessments will be performed pre-dose on Cycle 1 Day 1, and prior to infusions in Cycles 2, 4, and 6. For patients remaining on treatment, assessments will continue every 3 cycles thereafter. Pharmacokinetic (PK) profiles will be evaluated in two distinct subgroups of 10 patients each. For the intensive PK sampling subgroup, assessments are concentrated in the first three cycles: Cycle 1 monitoring includes Day 1 (pre-dose, end of infusion, 2, and 6 hours post-infusion), Day 2 (24 hours), Day 6 (120 hours), Day 10 (216 hours), and Day 15 (pre-dose). Following pre-dose samples on Cycle 2 (Days 1 and 15) and Cycle 3 (Day 1), a second intensive window occurs on Cycle 3 Day 15 (pre-dose, end of infusion, 2, and 6 hours post-infusion) and continues through Days 16, 20, and 24. Subsequent samples are taken pre-dose on Day 1 of Cycles 4, 5, and 6, concluding at the EOT visit. In contrast, the sparse PK sampling subgroup will undergo limited assessments at Cycle 1 Day 1 (pre-dose and end of infusion), Cycle 1 Day 15 (pre-dose), and the first day of Cycles 2 and 3 (pre-dose and end of infusion), with a final sample collected at the EOT visit.

Conditions

  • Advanced Malignant Solid Tumor

Interventions

  • PRL3-ZUMABBiological

    PRL3-zumab is an humanized anti PRL3 antibody targeted to PRL3 antigen in cancer cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: Time Frame: From the date of first dose of study drug until first documented disease progression or date of death from any cause, whichever comes first, assessed up to 12 months.
  2. Time to Progression (TTP)Time frame: From the date of first dose of study drug until first documented disease progression, assessed up to 12 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou Cancer Hospital

    Hangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.